A new professional intelligence report published by Market.us with the title “The Global Estradiol Transdermal System Market” has the ability to help the decision-makers in the most important market ...

PRINCETON, N.J. and CHARLESTON, S.C., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced a new alliance with Afaxys Pharma, LLC to ...

Global Estradiol Transdermal System Market 2020-2029 attempts to offer significant and thoughtful insights into the current market situation and emerging growth dynamics. The report on Estradiol ...

Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI Twirla® (levonorgestrel and ethinyl ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON, D.C. — An estradiol transdermal system bested oral estrogen-only hormone therapy agents in terms of ...

PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the U.S. commercial launch of Twirla ® (levonorgestrel and ...

MIAMI, Fla. & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has acquired commercial rights to ...

PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an ...

TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use Consider ...

The good news here is that more women in perimenopause and menopause are getting the message about hormone therapy More women are using hormone replacement therapy during perimenopause and menopause.